Diabetes and Dyslipidemia

  • Henry N. Ginsberg
  • Catherine Tuck
Part of the Contemporary Cardiology book series (CONCARD)


Numerous prospective cohort studies have indicated that diabetes mellitus is associated with a three- to fourfold increase in risk for coronary heart disease (CHD) (1–3). The increase in risk is particularly evident in both younger age groups and in women. Women with type 2 diabetes appear to lose a great deal of the protection that characterizes nondiabetic females. Furthermore, patients with diabetes have a 50% greater in-hospital mortality and a twofold increased rate of death within 2 years of surviving a myocardial infarction. Overall, CHD is the leading cause of death in individuals with diabetes who are over the age of 35 years.


Glycemic Control Cholesteryl Ester Cholesteryl Ester Transfer Protein Coronary Heart Disease Event Fibric Acid Derivative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kannel WB, D’Agostino RB, Wilson PWF, Bleanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672–676.PubMedCrossRefGoogle Scholar
  2. 2.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctions. N Engl J Med 1998;339:229–234.PubMedCrossRefGoogle Scholar
  3. 3.
    Haffner SM. Management of dyslipidemia in adults with diabetes (Technical Review). Diabetes Care 1998;21:160–178.PubMedCrossRefGoogle Scholar
  4. 4.
    Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogensis. Diabetes Care 1991;14:839–855.PubMedCrossRefGoogle Scholar
  5. 5.
    Taskinen M–R. Hyperlipidaemia in diabetes. Baillieres Clin Endocrinol Metabol 1990;4:743–775.CrossRefGoogle Scholar
  6. 6.
    Betteridge DJ. Diabetes, lipoprotein metabolism and atherosclerosis. Bri Med Bull 1989;45:285–311.Google Scholar
  7. 7.
    Dunn FL. Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 1990;6:47.PubMedCrossRefGoogle Scholar
  8. 8.
    Ginsberg HN. Lipoprotein physiology. In: Hoeg J, ed. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia, PA, 1998, pp. 1–14.Google Scholar
  9. 9.
    Cooper AD. Hepatic uptake of chylomicron remnants. Review. J Lipid Res 1997;38:2173–2192.PubMedGoogle Scholar
  10. 10.
    Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B–containing lipoproteins by the liver. Review. Biochim Biophys Acta 1999;1440:1–31.CrossRefGoogle Scholar
  11. 11.
    Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein–B kinetics in non–insulin–dependent diabetes mellitus. Diabetes 1982; 31:217–225.PubMedCrossRefGoogle Scholar
  12. 12.
    Ginsberg HN, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose lowering. J Cardiovasc Risk 1999;6:337–347.PubMedGoogle Scholar
  13. 13.
    Austin MA, Krauss RM. LDL density and atherosclerosis. JAMA 1995;273:115.PubMedCrossRefGoogle Scholar
  14. 14.
    Lopes–Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycosylation of low–density lipoprotein enhances cholesteryl ester synthesis in human monocyte–derived macrophages. Diabetes 1988; 37:550–557.CrossRefGoogle Scholar
  15. 15.
    Phillips MC, Gillotte KL, Haynes MP, Johnson WJ, Lund–Katz S, Rothblat GH. Mechanisms of high density lipoprotein–mediated efflux of cholesterol from cell plasma membranes. Atherosclerosis 1998; 137(Suppl): S 13–S 17.Google Scholar
  16. 16.
    Trigatti B, Rigotti A, Krieger M. The role of the high–density lipoprotein receptor SR–BI in cholesterol metabolism. Curr Opin Lipidol 2000;11:123–131.PubMedCrossRefGoogle Scholar
  17. 17.
    Horowitz BS, Goldberg IJ, Merab J, Vanni T, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A–I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993;91:1743–1760.PubMedCrossRefGoogle Scholar
  18. 18.
    Grundy SM. Dietary therapy in diabetes mellitus. Diabetes Care 1991;14:796–808.PubMedCrossRefGoogle Scholar
  19. 19.
    Howard BV. Diabetes and plasma lipoproteins in Native Americans. Studies of the Pima Indians. Diabetes Care 1993;16:284–291.CrossRefGoogle Scholar
  20. 20.
    Amercan Diabetes Association: nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 1990;22:S42–S45.Google Scholar
  21. 21.
    Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with noninsulin–dependent diabetes mellitus. JAMA 1994;271:1421–1428.PubMedCrossRefGoogle Scholar
  22. 22.
    Garg A, Bonanome A, Grundy SM, Zhang Z, Unger RH. Comparison of a high–carbohydrate diet with a high–monounsaturated–fat diet in patients with non–insulin-dependent diabetes mellitus. N Engl J Med 1988;319:829–834.PubMedCrossRefGoogle Scholar
  23. 23.
    Anderson JW, Gustafson NJ, Bryant CA, Tietyen-Clark CA. Dietary fiber and diabetes: a comprehensive review and practical application. J Am Diet Assoc 1987;87:1189.PubMedGoogle Scholar
  24. 24.
    Anderson JW. Dietary fiber and diabetes: what else do we need to know? Diabetes Res Clin Pract 1992; 17:71–73.PubMedCrossRefGoogle Scholar
  25. 25.
    American Diabetes Association: management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 1999;22:S56–S59.Google Scholar
  26. 26.
    Harris WS. Dietary fish oil and blood lipids. Review. Curr Opin Lipidol 1996;7:3–7.PubMedCrossRefGoogle Scholar
  27. 27.
    National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1333–1445.CrossRefGoogle Scholar
  28. 28.
    Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153–163.PubMedCrossRefGoogle Scholar
  29. 29.
    Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non–insulin dependent diabetes mellitus. JAMA 1990;264:723–726.PubMedCrossRefGoogle Scholar
  30. 30.
    Goldberg A, Alagona P, Capuzzi DM, et al. Multipledose efficacy and safety of an extended–release form of niacin in the management of hyperlipidemia. Am J Cardio12000;85:1101–1105.Google Scholar
  31. 31.
    Ginsberg HN. Drug therapy of hypercholesterolemia. In: Rifkind B, ed. Lowering Cholesterol in HighRisk Individivals and Populations. Marcel Dekker, New York, 1995, pp. 271–290.Google Scholar
  32. 32.
    Ginsberg HN. Effects of statins on triglyceride metabolism. Am J Cardiol 1998;81:32B–35B.CrossRefGoogle Scholar
  33. 33.
    Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81:66B–69B.CrossRefGoogle Scholar
  34. 34.
    Pyorala K, Pedersen TR, Kjekshus J, Faegerman 0, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease. A subgroup analysis of the Scandanavian Simvastatin Survival Study. Diabetes Care 1997;20:614–620.PubMedCrossRefGoogle Scholar
  35. 35.
    Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513–2519.PubMedCrossRefGoogle Scholar
  36. 36.
    Steiner G. Effects of various lipid-lowering treatments in diabetes. J Cardiovasc Pharm 1990;16:S35S38.Google Scholar
  37. 37.
    Frick MH, Elo H, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237–1245.PubMedCrossRefGoogle Scholar
  38. 37a.
    Rubins HB, Robbins SJ, Collins P, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999;341:410–418.PubMedCrossRefGoogle Scholar
  39. 38.
    Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol 1997;17:1793–1799.PubMedCrossRefGoogle Scholar
  40. 39.
    Tikkanen MJ, Laakso M, Ilmonen, M, et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998;21:477–481.PubMedCrossRefGoogle Scholar
  41. 40.
    Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prey Med 1991;20:47–63.CrossRefGoogle Scholar
  42. 41.
    Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 1997;17:1822–1829.PubMedCrossRefGoogle Scholar
  43. 42.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study Research Group. JAMA 1998;280:605–613.PubMedCrossRefGoogle Scholar
  44. 43.
    Andersson B, Mattsson L-A, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:638–643.PubMedCrossRefGoogle Scholar
  45. 44.
    Brussaard HE, Gevers Leuven JA, Kluft C, et al. Effect of 17beta-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. Arterioscler Thromb Vasc Biol 1997;17:324–330.PubMedCrossRefGoogle Scholar
  46. 45.
    Friday KE. Estronen replacement therapy improves glycemic control and high density lipoprotein cholesterol concentrations in post-menopausal type 2 diabetic women. Diabetes 1998;47:(Suppl 1): A357.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Henry N. Ginsberg
  • Catherine Tuck

There are no affiliations available

Personalised recommendations